Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Docetaxel and Ifosfamide as First-Line Chemotherapy in Women With Metastatic Breast Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Active	21 to 75	Other	GOCS-02-BR-01 NCI-V01-1670, NCT00026078

Trial Description

Purpose:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Phase II trial to study the effectiveness of docetaxel and ifosfamide in treating women who have metastatic breast cancer.

Eligibility:

Eligibility criteria include the following:

• 21-75 years old
• Measurable disease
• No CNS metastases
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive an infusion of docetaxel on day 1 followed by an infusion of ifosfamide on days 1-3. Treatment may continue every 4 weeks for as long as benefit is shown. Quality of life will be assessed periodically. Patients will be evaluated every 3 months.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Grupo Oncologico Cooperativo del Sur

Bernardo A. Leone, MD, Protocol chair		Ph: 54-299-448-5247 Email: bleone@satlink.com

Argentina
	Mar del Plata
	C.R I O.
		Ricardo Rodriguez, MD	Ph:  54-223-479-3283
			Email: ricrodri@copetel.com.ar
	Tres Arroyos
	Centro Oncologico Tres Arroyos
		Maria Ester Dominguez, MD	Ph:  0983-33450
			Email: medominquez@3net.com.ar
Buenos Aires
	Bahia Blanca
	Grupo Oncologico Cooperativo del Sur
		Juan Eduardo Perez, MD	Ph:  54-291-452-5667
			Email: jperez@criba.edu.ar
	Policlinica Privada Instituto De Medicina Nuclear
		Alberto Omar Romero, MD	Ph:  54-291-453-9848
			Email: gocsbhb@bvconline.com.ar
		Mario Raul Machiavelli, MD	Ph:  54-91-39-848
	Gonnet
	St. Joseph Medical Center
		Sergio Grasso, MD	Ph:  54-221-4845088
La Pampa
	Santa Rosa
	Sanatorio Santa Rosa S.R.L.
		Eduardo Heriberto Ortiz, MD	Ph:  54-2954-29-715
Neuquen
	Neuquen
	Unidad Oncologica Del Neuquen
		Bernardo A. Leone, MD	Ph:  54-299-448-5247
			Email: bleone@satlink.com
Mexico
Jalisco
	Guadalajara
	Centro Medico Nacional de Occidente
		Gilberto Morgan Villela, MD	Ph:  523-641-5081

Registry Information
Official Title		Docetaxel (DTX) - Ifosfamide (IFX) As First Line Chemotherapy In Metastatic Breast Cancer
Trial Start Date		2001-03-15
Registered in ClinicalTrials.gov		NCT00026078
Date Submitted to PDQ		2001-08-10
Information Last Verified		2006-11-28

Back to Top